Participants will be aged ≥ 18 years, aware of their HIV status and the diagnosis of malignancy, have a plasma viral load of < 50 HIV-1 RNA copies/ml (on suppressive HAART) at enrolment and be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel.
There is no intervention for this study. Blood samples will be taken and if available from routine care surplus cerebrospinal fluid.

Cancer

No intervention for this study

Chelsea and Westminster Hospital NHS Foundation Trust

Prospective HIV Chemotherapy Cohort Study

Prospective Observational Study of HIV Positive Individuals on Suppressive HAART With Malignancy Undergoing Chemotherapy

Comparison of proviral DNA quantification between baseline and at 12 weeks postcompletion of chemotherapy

Quantification of proviral DNA (intracellular DNA/MRNA)

Quantification of HIV-1 viral RNA transcripts

Quantification of HIV-1 ultra-low viral load (UL-VL)

Quantification of immune activation levels

Imperial College London

Imperial College Healthcare NHS Trust

Neuroblastoma

Brain Tumors

Solid Tumors

Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg
Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg
Patients receive during 5 days (Day 1 to Day 5):
Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes

Temozolomide/Hycamtin (Topotecan)

Institut Gustave Roussy

Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours

Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours

Gustave Roussy, Cancer Campus, Grand Paris

St. Anna Kinderkrebsforschung

Catholic University of the Sacred Heart

Erasmus Medical Center

Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.

ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)

Beth Israel Deaconess Medical Center

Montefiore-Einstein Cancer Center

A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors

A Phase 1, Dose Escalation Study of the Safety and Pharmacokinetics of ALB 109564(a) Administered Intravenously Every 3 Weeks to Subjects With Advanced Solid Tumors

Albany Molecular Research, Inc.

Westat

HIV Infections

Giant Lymph Node Hyperplasia

Rituximab

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB)

French National Agency for Research on AIDS and Viral Hepatitis

Hoffmann-La Roche

alkaloid

sarcoma

alkaloid/sarcoma

Prospective HIV Chemotherapy Cohort Study

Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours

A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

A legteljesebb gyógynövény-adatbázis, amelyet a tudomány támogat